Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study

BACKGROUND: Programmed death‐1 (PD‐1) blocking antibodies have been shown to improve progression‐free survival (PFS) and overall survival in a subset of patients with non–small cell lung cancer (NSCLC). However, the objective response rate with these agents remains low, and the vast majority of NSCL...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Thorac Cancer
Main Authors: Han, Ying, Mu, Di, Liu, Ting, Zhang, Huan, Zhang, Jiali, Li, Shuzhan, Wang, Rui, Du, Weijiao, Hui, Zhenzhen, Zhang, Xinwei, Ren, Xiubao
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons Australia, Ltd 2020
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7812069/
https://ncbi.nlm.nih.gov/pubmed/33150733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13731
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki